In conclusion, the small leucine-rich proteoglycan decorin exerts cardiocytoprotective effects against SI/R, suggesting a therapeutic potential of exogenously administered decorin for the treatment of acute myocardial infarction. Here, DCN is linked to acute myocardial infarction.